Hello,
In case some of you haven't seen the three articles related to
aminoguanidine you can go to this web site and look through the
abstracts.  While you read the abstracts keep in mind the FDA offered
this drug a "fast track" if it was resubmitted.

The first abstract is safety profile - 2 people progressed to ESRD and
another recovered.  I have no idea why the article states the 3rd
recovered.  If they are referring to me - I did not recover and have a
number of health problems from this drug study.  Maybe Alteon isn't
aware of these because they removed me from the drug study?

Eileen is one of the people who progressed to ESRD and has had a
horrible time with her kidney transplant. I wonder what happened to the
other person?

http://www.asn-online.com/

     [A0941] Pimagedine (PG) Safety Profile in Patients with Type I
Diabetes Mellitus (DM). Frederick Whittier, Bruce
     Spinowitz, Jean-Paul Wuerth, Kenneth Cartwright, for the ACTION 1
Investigator Group. Mercy Medical Center, Canton, OH;
     New York Hospital Medical Center of Queens, New York, NY; Alteon
Inc., Ramsey, NJ.
[A0914] Pimagedine (PG) Reduces Progression of Retinopathy and Lowers
Lipid Levels in Patients with Type 1 Diabetes
     Mellitus (DM). Philip Raskin, Daniel Cattran, Mark Williams,
Jean-Paul Wuerth, Kenneth Cartwright, for the ACTION 1
     Investigator Group. U. of Texas Southwestern Medical Center,
Dallas, TX; Toronto General Hospital, Toronto, Canada; Joslin
     Diabetes Center, Boston, MA; Alteon Inc., Ramsey, NJ.
[A0786] Pimagedine (PG) Lowers Total Urinary Protein (TUP) and Slows
Progression of Overt Diabetic Nephropathy in
     Patients with Type 1 Diabetes Mellitus (DM). Gerald Appel, Kline
Bolton, Barry Freedman, Jean-Paul Wuerth, Kenneth
     Cartwright, for the ACTION 1 Investigator Group. Columbia
Presbyterian Medical Center, New York, NY; U. of Virginia Medical
     Center, Charlottesville, VA; North Carolina Baptist Hospital,
Winston-Salem, NC; Alteon Inc., Ramsey, NJ.

CYA - this post is my opinion and from personal experience only.

***************
Looking for information---- If you have information about this
conference call please email me.  mailto:Margaret_D...@juno.com

Alteon Inc. Announces Investor Update Conference Call, January 7, 2000,
2:00 PM

                   Ramsey, New Jersey, January 6, 2000 ­ Alteon Inc.
(OTCBB: ALTN) announced today that it will hold a
                   conference call for all investors on Friday, January
7, 2000 at 2:00 p.m. eastern time.

                   “We have received numerous phone calls regarding the
status of Alteon,” said Kenneth I. Moch, President and
                   Chief Executive Officer. “While we encourage and
respond to all individual investor inquiries, this conference
                   call will enable us to update all interested
shareholders on the company’s status and that of its lead research
                   programs.”

                   Anyone interested in participating in the conference
call should R.S.V.P. to Susan M. Pietropaolo, Manager of
                   Corporate Communications, at 201-818-5537 (direct
line), fax 201-934-8880, or e-mail,
                   spietropa...@alteonpharma.com. Participants are also
encouraged to fax or e-mail specific questions to the
                   company. There will be a full question and answer
period on the conference call.

                Eastern Time

Sorry this is so long.
Margaret

Sent via Deja.com http://www.deja.com/
Before you buy.